35 related articles for article (PubMed ID: 11011333)
1. LocalControl: An R Package for Comparative Safety and Effectiveness Research.
Lauve NR; Nelson SJ; Young SS; Obenchain RL; Lambert CG
J Stat Softw; 2020; 96(4):. PubMed ID: 34349611
[TBL] [Abstract][Full Text] [Related]
2. Sensitivity analysis for causal inference using inverse probability weighting.
Shen C; Li X; Li L; Were MC
Biom J; 2011 Sep; 53(5):822-37. PubMed ID: 21770046
[TBL] [Abstract][Full Text] [Related]
3. Effects of changing clinical practice on costs and outcomes of percutaneous coronary intervention between 1998 and 2002.
Denvir MA; Lee AJ; Rysdale J; Prescott RJ; Eteiba H; Starkey IR; Pell JP; Walker A
Heart; 2007 Feb; 93(2):195-9. PubMed ID: 16849373
[TBL] [Abstract][Full Text] [Related]
4. Choice of GPIIb/IIIa antagonist in percutaneous coronary intervention: how should economic criteria be factored in?
Le Pen C; Lilliu H
Pharm World Sci; 2005 Apr; 27(2):83-91. PubMed ID: 15999917
[TBL] [Abstract][Full Text] [Related]
5. Abciximab: an updated review of its therapeutic use in patients with ischaemic heart disease undergoing percutaneous coronary revascularisation.
Ibbotson T; McGavin JK; Goa KL
Drugs; 2003; 63(11):1121-63. PubMed ID: 12749745
[TBL] [Abstract][Full Text] [Related]
6. Abciximab therapy in percutaneous intervention: economic issues in the United States.
Goklaney AK; Murphy JD; Hillegass WB
Eur Heart J; 1998 Apr; 19 Suppl D():D52-8. PubMed ID: 9597522
[TBL] [Abstract][Full Text] [Related]
7. The economics of adjunctive therapies in coronary angioplasty: drugs, devices, or both?
Oh PI; Cohen EA; Mittmann N; Seung SJ
Can J Clin Pharmacol; 2004; 11(2):e202-11. PubMed ID: 15520474
[TBL] [Abstract][Full Text] [Related]
8. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators.
Lincoff AM; Califf RM; Moliterno DJ; Ellis SG; Ducas J; Kramer JH; Kleiman NS; Cohen EA; Booth JE; Sapp SK; Cabot CF; Topol EJ
N Engl J Med; 1999 Jul; 341(5):319-27. PubMed ID: 10423466
[TBL] [Abstract][Full Text] [Related]
9. Costs and effects in therapy for acute coronary syndromes: the case of abciximab in high-risk patients undergoing percutaneous transluminal coronary angioplasty in the EPIC study. Evaluation of 7E3 for the Prevention of Ischemic Complications.
van Hout BA; Bowman L; Zelinger DJ; Simoons ML
Eur Heart J; 1998 Apr; 19 Suppl D():D59-66. PubMed ID: 9597523
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of the platelet glycoprotein IIb/IIIa inhibitor abciximab in Chinese patients undergoing high-risk angioplasty.
Chen YH; Chen JW; Wu TC; Ding PY; Wang SP; Chang MS
Zhonghua Yi Xue Za Zhi (Taipei); 2000 Jan; 63(1):8-15. PubMed ID: 10645045
[TBL] [Abstract][Full Text] [Related]
11. Abciximab provides cost-effective survival advantage in high-volume interventional practice.
Kereiakes DJ; Obenchain RL; Barber BL; Smith A; McDonald M; Broderick TM; Runyon JP; Shimshak TM; Schneider JF; Hattemer CR; Roth EM; Whang DD; Cocks D; Abbottsmith CW
Am Heart J; 2000 Oct; 140(4):603-10. PubMed ID: 11011333
[TBL] [Abstract][Full Text] [Related]
12. Abciximab: cost-effective survival advantage in clinical trials and clinical practice.
Young JJ; Kereiakes DJ
Am Heart J; 2000 Dec; 140(6 Suppl):S148-53. PubMed ID: 11100009
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
